scholarly journals The Therapeutic Potential of Common Herbal and Nano-Based Herbal Formulations against Ovarian Cancer: New Insight into the Current Evidence

2021 ◽  
Vol 14 (12) ◽  
pp. 1315
Author(s):  
Fatemeh Rezaei-Tazangi ◽  
Hossein Roghani-Shahraki ◽  
Mahdi Khorsand Ghaffari ◽  
Firoozeh Abolhasani Zadeh ◽  
Aynaz Boostan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Water Solubility ◽  
Therapeutic Potential ◽  
Disease Recurrence ◽  
Current Evidence ◽  
Herbal Products ◽  
Anti Cancer ◽  
Cancer Agent ◽  
Gynecological Disorder ◽  
Herbal Formulations

Ovarian cancer (OCa) is characterized as one of the common reasons for cancer-associated death in women globally. This gynecological disorder is chiefly named the “silent killer” due to lacking an association between disease manifestations in the early stages and OCa. Because of the disease recurrence and resistance to common therapies, discovering an effective therapeutic way against the disease is a challenge. According to documents, some popular herbal formulations, such as curcumin, quercetin, and resveratrol, can serve as an anti-cancer agent through different mechanisms. However, these herbal products may be accompanied by some pharmacological limitations, such as poor bioavailability, instability, and weak water solubility. On the contrary, using nano-based material, e.g., nanoparticles (NPs), micelles, liposomes, can significantly solve these limitations. Therefore, in the present study, we will summarize the anti-cancer aspects of these herbal and-nano-based herbal formulations with a focus on their mechanisms against OCa.

scholarly journals Development of Small-Molecule STING Activators for Cancer Immunotherapy

Biomedicines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 33
Author(s):  
Hee Ra Jung ◽  
Seongman Jo ◽  
Min Jae Jeon ◽  
Hyelim Lee ◽  
Yeonjeong Chu ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Cyclic Gmp ◽  
Therapeutic Potential ◽  
Interferon Response ◽  
Type I ◽  
Anti Cancer ◽  
Cancer Agent ◽  
Sting Pathway

In cancer immunotherapy, the cyclic GMP–AMP synthase–stimulator of interferon genes (STING) pathway is an attractive target for switching the tumor immunophenotype from ‘cold’ to ‘hot’ through the activation of the type I interferon response. To develop a new chemical entity for STING activator to improve cyclic GMP-AMP (cGAMP)-induced innate immune response, we identified KAS-08 via the structural modification of DW2282, which was previously reported as an anti-cancer agent with an unknown mechanism. Further investigation revealed that direct STING binding or the enhanced phosphorylation of STING and downstream effectors were responsible for DW2282-or KAS-08-mediated STING activity. Furthermore, KAS-08 was validated as an effective STING pathway activator in vitro and in vivo. The synergistic effect of cGAMP-mediated immunity and efficient anti-cancer effects successfully demonstrated the therapeutic potential of KAS-08 for combination therapy in cancer treatment.

Bromelain’s activity and potential as an anti-cancer agent: Current evidence and perspectives

2010 ◽  
Vol 290 (2) ◽  
pp. 148-156 ◽  
Author(s):  
Katya Chobotova ◽  
Ann B. Vernallis ◽  
Fadzilah Adibah Abdul Majid
Keyword(s):  
Current Evidence ◽  
Anti Cancer ◽  
Cancer Agent

scholarly journals Dual Actions of Ketorolac in Metastatic Ovarian Cancer

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1049 ◽  
Author(s):  
Hudson ◽  
Cook ◽  
Grimes ◽  
Muller ◽  
Adams ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Inflammatory Responses ◽  
Residual Disease ◽  
Disease Recurrence ◽  
Racemic Mixture ◽  
Clinical Issue ◽  
Anti Cancer ◽  
Simultaneous Inhibition ◽  
Inflammatory Drugs

Cytoreductive surgery and chemotherapy are cornerstones of ovarian cancer treatment, yet disease recurrence remains a significant clinical issue. Surgery can release cancer cells into the circulation, suppress anti-tumor immunity, and induce inflammatory responses that support the growth of residual disease. Intervention within the peri-operative window is an under-explored opportunity to mitigate these consequences of surgery and influence the course of metastatic disease to improve patient outcomes. One drug associated with improved survival in cancer patients is ketorolac. Ketorolac is a chiral molecule administered as a 1:1 racemic mixture of the S- and R-enantiomers. The S-enantiomer is considered the active component for its FDA indication in pain management with selective activity against cyclooxygenase (COX) enzymes. The R-enantiomer has a previously unrecognized activity as an inhibitor of Rac1 (Ras-related C3 botulinum toxin substrate) and Cdc42 (cell division control protein 42) GTPases. Therefore, ketorolac differs from other non-steroidal anti-inflammatory drugs (NSAIDs) by functioning as two distinct pharmacologic entities due to the independent actions of each enantiomer. In this review, we summarize evidence supporting the benefits of ketorolac administration for ovarian cancer patients. We also discuss how simultaneous inhibition of these two distinct classes of targets, COX enzymes and Rac1/Cdc42, by S-ketorolac and R-ketorolac respectively, could each contribute to anti-cancer activity.

A review of eugenol-based nanomedicine: Recent Advancements

2020 ◽  
Vol 16 ◽  
Author(s):  
Mohammed Asadullah Jahangir ◽  
Mohamad Taleuzzaman ◽  
Sarwar Beg ◽  
Surajpal Verma ◽  
Sadaf Jamal Gilani ◽  
...  
Keyword(s):  
Therapeutic Potential ◽  
Chemical Properties ◽  
Aqueous Solubility ◽  
Bioactive Compound ◽  
Anti Cancer ◽  
Herbal Plants ◽  
Cancer Agent ◽  
Therapeutic Activities ◽  
Different Sources ◽  
Holy Basil

: Eugenol is a bioactive compound frequently available in many herbal plants. The different sources reported for eugenol are clove, cinnamon, holy basil, and pepper. There are several therapeutic activities reported for eugenol as antioxidant, antimicrobial, anesthetic, antiinflammatory, anti-carcinogenic, neuroprotective agent, anti-diabetic and anti-cancer agent. However, due to limited aqueous solubility they have poor bioavailability. Their therapeutic potential has been enhanced with the eugenol nano-formulations developed as liposome, nanoparticles, microemulsions and micelles. This article extensively reviews the chemical properties, pharmacological properties, andeugenol nano-formulations with their biological activity.

Increasing Solubility of Poorly Water Soluble Drug Resveratrol by Surfactants and Cyclodextrins

2011 ◽  
Vol 418-420 ◽  
pp. 2231-2234 ◽  
Author(s):  
Mont Kumpugdee-Vollrath ◽  
Yvonne Ibold
Keyword(s):  
Solid Dispersion ◽  
Water Solubility ◽  
Solid Dispersions ◽  
Water Soluble ◽  
Dispersion Phase ◽  
Water Soluble Drug ◽  
Vis Spectroscopy ◽  
Anti Cancer ◽  
Cancer Agent ◽  
Span 60

Resveratrol (Res) is a polyphenolic secondary natural substance and can be used as anti-inflammatory, anti-aging, anti-heart disease and anti-cancer agent. However, Res has low water solubility which causes a low bioavailability in human body. In order to increase solubility we have prepared different inclusion complexes with native ((α, β, γ) and modified (2-hydroxypropyl-beta, dimethyl-beta) cyclodextrins (Cd) as well as solid dispersions using several surfactants (Imwitor 742, Imwitor 928, PEG 6000, Span 40, Span 60, Solutol HS15) with Res. The solubility of all mixtures was determined by UV-VIS spectroscopy at the wavelength of 305 nm. Regarding the Cd, the complex of Res with 2-hydroxypropyl-beta-Cd at a ratio of 1:3 showed the highest water solubility (248210 g/l). Concerning the surfactants, the solid dispersion from Res and Solutol HS15 showed the highest water solubility (16140 g/l). The complexation and the solid dispersion phase were confirmed by DSC. The results will be a basis for better formulation of resveratrol with higher bioavailability.

scholarly journals Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model

PLoS ONE ◽  
2012 ◽  
Vol 7 (4) ◽  
pp. e34443 ◽  
Author(s):  
Richard G. Moore ◽  
Thilo S. Lange ◽  
Katina Robinson ◽  
Kyu K. Kim ◽  
Alper Uzun ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Fatty Acid ◽  
Fatty Acid Synthesis ◽  
Xenograft Model ◽  
Acid Synthesis ◽  
Vitamin D2 ◽  
Anti Cancer ◽  
Cancer Agent

Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines

2011 ◽  
Vol 123 (2) ◽  
pp. 370-378 ◽  
Author(s):  
Laurent Brard ◽  
Thilo S. Lange ◽  
Katina Robison ◽  
Kyu Kwang Kim ◽  
Tahniyath Ara ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Lines ◽  
Anti Cancer ◽  
Cancer Agent

The effects of itraconazole as anti-cancer agent in epithelial ovarian cancer

2015 ◽  
Vol 137 ◽  
pp. 203
Author(s):  
J.W. Lee ◽  
Y.Y. Lee ◽  
W.Y. Kim ◽  
A. Yoon ◽  
T.J. Kim ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Anti Cancer ◽  
Cancer Agent

Tetrahydrocurcumin, Curcumin, and 5-Fluorouracil Effects on Human Esophageal Carcinoma Cells

2019 ◽  
Vol 19 (8) ◽  
pp. 1012-1020 ◽  
Author(s):  
Emily G. Pendleton ◽  
Roudabeh J. Jamasbi ◽  
Michael E. Geusz
Keyword(s):  
Cell Proliferation ◽  
Cell Lines ◽  
Water Solubility ◽  
Carcinoma Cells ◽  
Cancer Drug ◽  
Novel Treatments ◽  
Diet Supplements ◽  
Anti Cancer ◽  
Traditional Therapies ◽  
Cancer Agent

Background: Esophageal cancer responds poorly to traditional therapies, and novel treatments are needed. The phytochemical curcumin is a potential treatment for Esophageal Squamous Cell Carcinoma (ESCC). A curcumin metabolite, tetrahydrocurcumin (THCUR), has anti-cancer effects and greater bioavailability than curcumin. Objective: Evaluate THCUR as an anti-cancer agent relative to curcumin and a standard cancer drug, 5-fluorouracil (5-FU), along with treatment interactions. Materials and Methods: Assay cell proliferation and viability following individual and combined delivery of the compounds to three ESSC cell lines (TE-1, TE-8, and KY-5) that have different percentages of Cancer Stem Cells (CSCs). Results: Curcumin was significantly more effective than 5-FU in all three cell lines. It also had the greatest effect on KY-5 cells, which have the highest CSC properties, consistent with the ability of curcumin to target CSCs. Effects on ESCC cell proliferation were not detected from 40µM THCUR, a dosage above the IC50 of curcumin and 5-FU. However, THCUR at this dosage in combination with 5-FU significantly suppressed TE-1 cell proliferation, but 5-FU alone did not. As TE-1 has low CSC properties relative to the two other cell lines, it was expected to have the least resistance to chemotherapeutic treatments. Surprisingly, TE-1 was the most resistant to inhibition by 5-FU. Conclusion: These results and the greater stability and water solubility of THCUR than curcumin support further testing of THCUR in combination with standard treatments, particularly for chemoresistant ESCC. In contrast to concerns that curcuminoids taken by patients through diet or diet supplements might interfere with chemotherapy, suppression of 5-FU efficacy by curcumin was not observed.

Sign in / Sign up

Export Citation Format

Share Document